Gastrointestinal tumor antigens

Gastrointestinal tumor antigens (GITA) represent a diverse and heterogeneous category of molecular markers, primarily glycoproteins and carbohydrate structures, that are overexpressed on the surface of malignant cells in the digestive tract, including the stomach, colon, pancreas, and biliary system. Prominent examples include Carcinoembryonic Antigen (CEA), Carbohydrate Antigen 19-9 (CA 19-9), and Guanylate Cyclase 2C (GUCY2C), which play significant roles in tumor biology such as cell-cell adhesion, signal transduction, and immune evasion. In clinical oncology, these antigens are widely utilized as serum biomarkers for diagnosis, prognosis, and monitoring treatment response. They also serve as critical therapeutic targets for various modalities, including monoclonal antibodies, antibody-drug conjugates (ADCs) like AbGn-107, and chimeric antigen receptor (CAR) T-cell therapies. For instance, AbGn-107 targets the AG-7 carbohydrate antigen found in various GI malignancies, while GUCY2C is a primary target for T-cell redirecting therapies in colorectal cancer. However, the development of these therapies is often complicated by the low-level expression of these antigens in healthy tissues, which can lead to 'on-target, off-tumor' toxicities, necessitating the use of highly selective targeting strategies.

Other names

Gastrointestinal cancer antigensGICAGastrointestinal tumor-associated antigensGATACarbohydrate antigen 19-9CA 19-9AG-7 antigenCarcinoembryonic antigenCEA

Targeting of tumor-associated antigens via antibody-drug conjugates, CAR-T cells, or monoclonal antibodies to induce cell death through direct cytotoxicity, immune redirection, or inhibition of oncogenic signaling.